Pharmacokinetics of risperidone in chronic schizophrenic patients

R. L. Borison, B. Diamond, Ananda Pathiraja, R. C. Meibach

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In a randomized, crossover study, 24 schizophrenic patients received a single 4-mg dose of risperidone in caplet or tablet form. Each of the two study periods lasted 5 days. Blood samples to determine (by radioimmunoassay) plasma levels of risperidone and its major metabolite, 9-hydroxy-risperidone (9-OH-risperidone), were obtained each day. The two formulations of risperidone were bioequivalent. Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng · hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng · hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours. These results demonstrate that the active moiety (risperidone plus 9-OH-risperidone) has a half-life of 23 hours and reveal a pool of risperidone (terminal half-life, 14.9 hours) that may allow twice-daily or even once-daily dosing.

Original languageEnglish (US)
Pages (from-to)193-197
Number of pages5
JournalPsychopharmacology Bulletin
Volume30
Issue number2
StatePublished - Jan 1 1994

Fingerprint

Risperidone
Pharmacokinetics
Half-Life
Area Under Curve
Cross-Over Studies
Tablets
Radioimmunoassay

Keywords

  • atypical neuroleptic
  • major
  • pharmacokinetics
  • risperidone
  • schizophrenia
  • tranquilizing agents

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Borison, R. L., Diamond, B., Pathiraja, A., & Meibach, R. C. (1994). Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacology Bulletin, 30(2), 193-197.

Pharmacokinetics of risperidone in chronic schizophrenic patients. / Borison, R. L.; Diamond, B.; Pathiraja, Ananda; Meibach, R. C.

In: Psychopharmacology Bulletin, Vol. 30, No. 2, 01.01.1994, p. 193-197.

Research output: Contribution to journalArticle

Borison, RL, Diamond, B, Pathiraja, A & Meibach, RC 1994, 'Pharmacokinetics of risperidone in chronic schizophrenic patients', Psychopharmacology Bulletin, vol. 30, no. 2, pp. 193-197.
Borison, R. L. ; Diamond, B. ; Pathiraja, Ananda ; Meibach, R. C. / Pharmacokinetics of risperidone in chronic schizophrenic patients. In: Psychopharmacology Bulletin. 1994 ; Vol. 30, No. 2. pp. 193-197.
@article{df2f0d78605a472fbf3b4b3941f8ab3f,
title = "Pharmacokinetics of risperidone in chronic schizophrenic patients",
abstract = "In a randomized, crossover study, 24 schizophrenic patients received a single 4-mg dose of risperidone in caplet or tablet form. Each of the two study periods lasted 5 days. Blood samples to determine (by radioimmunoassay) plasma levels of risperidone and its major metabolite, 9-hydroxy-risperidone (9-OH-risperidone), were obtained each day. The two formulations of risperidone were bioequivalent. Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng · hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng · hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours. These results demonstrate that the active moiety (risperidone plus 9-OH-risperidone) has a half-life of 23 hours and reveal a pool of risperidone (terminal half-life, 14.9 hours) that may allow twice-daily or even once-daily dosing.",
keywords = "atypical neuroleptic, major, pharmacokinetics, risperidone, schizophrenia, tranquilizing agents",
author = "Borison, {R. L.} and B. Diamond and Ananda Pathiraja and Meibach, {R. C.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "30",
pages = "193--197",
journal = "Psychopharmacology Service Center bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of risperidone in chronic schizophrenic patients

AU - Borison, R. L.

AU - Diamond, B.

AU - Pathiraja, Ananda

AU - Meibach, R. C.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - In a randomized, crossover study, 24 schizophrenic patients received a single 4-mg dose of risperidone in caplet or tablet form. Each of the two study periods lasted 5 days. Blood samples to determine (by radioimmunoassay) plasma levels of risperidone and its major metabolite, 9-hydroxy-risperidone (9-OH-risperidone), were obtained each day. The two formulations of risperidone were bioequivalent. Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng · hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng · hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours. These results demonstrate that the active moiety (risperidone plus 9-OH-risperidone) has a half-life of 23 hours and reveal a pool of risperidone (terminal half-life, 14.9 hours) that may allow twice-daily or even once-daily dosing.

AB - In a randomized, crossover study, 24 schizophrenic patients received a single 4-mg dose of risperidone in caplet or tablet form. Each of the two study periods lasted 5 days. Blood samples to determine (by radioimmunoassay) plasma levels of risperidone and its major metabolite, 9-hydroxy-risperidone (9-OH-risperidone), were obtained each day. The two formulations of risperidone were bioequivalent. Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278.0 and 716.9 ng · hr/mL; AUC from 0 to infinity, 291.9 and 762.4 ng · hr/mL; peak plasma concentration, 33.0 and 44.5 ng/mL; time to peak concentration, 1.39 and 1.78 hours; and elimination half-life, 14.93 and 23.04 hours. These results demonstrate that the active moiety (risperidone plus 9-OH-risperidone) has a half-life of 23 hours and reveal a pool of risperidone (terminal half-life, 14.9 hours) that may allow twice-daily or even once-daily dosing.

KW - atypical neuroleptic

KW - major

KW - pharmacokinetics

KW - risperidone

KW - schizophrenia

KW - tranquilizing agents

UR - http://www.scopus.com/inward/record.url?scp=0028050644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028050644&partnerID=8YFLogxK

M3 - Article

C2 - 7530379

AN - SCOPUS:0028050644

VL - 30

SP - 193

EP - 197

JO - Psychopharmacology Service Center bulletin

JF - Psychopharmacology Service Center bulletin

SN - 0048-5764

IS - 2

ER -